BRAF and thyroid cancer: Mouse models with BRAF V600E andp53 mutations develop poorly differentiated thyroid cancers.4 In humans, BRAF V600E mutation is commonly seen in 20% to50% of patients with ATC.5 Targeted combination therapy using a BRAF inhibitor, dabrafenib (Dab), with amitogen-activated extracellular protein kinase (MEK) inhibitor, trametinib (Tram),has shown significant promise6 and has recently received an accelerated Food and Drug Administrationapproval.